eCAM Advance Access originally published online on January 30, 2006
eCAM 2006 3(1):31-38; doi:10.1093/ecam/nek010
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review |
Role of Toll-like Receptors in Adjuvant-Augmented Immune Therapies
1Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine Kita-15, Nishi-7, Kita-ku Sapporo 060-8638, Japan, and 2Department of Immunogy, Osaka Medical Center for Cancer Nakamichi 1-3-2, Higashinari-ku, Osaka 537-8511, Japan
Effective therapeutic vaccines contain two primary constituents, antigen and adjuvant. Adjuvants consisting of microbial pattern molecules play a central role in vaccination. Successful vaccine requires efficient induction of antibody (Ab), type I interferons (IFN), cytokines/chemokines, cytotoxic T lymphocytes (CTL) and/or NK cells. Toll-like receptors (TLRs) in myeloid dendritic cells (mDC) essentially act as adjuvant receptors and sustain the molecular basis of adjuvant activity. Current consensus is that TLRs and their adapters introduce signals to preferentially induce IFN-
/ß, chemokines and proinflammatory cytokines, and mature mDC to augment antigen presentation. Although most of these data were obtained with mice, the results are presumed to be adaptable to humans. Whenever TLR pathway is activated in mDC, NK and/or CTL activation is promoted. For induction of antigen-specific CTL toward phagocytosed material, cross-priming must be induced in mDC, which is also sustained by TLR signaling in mDC. Since the TLR responses vary with different adjuvants, mDC functions are skewed depending on adjuvant-specific direction of mDC maturation. It appears that the directed maturation of mDC largely relies on selection of appropriate sets of TLRs and their adapter signaling pathways. Synthetic chimera molecules consisting of TLR agonists and target antigens are found to be effective in induction of CTL to eliminate target cells in vivo. Here, we review the role of human TLRs and adapters in a variety of host immune responses. We will also describe the relevance of adjuvants in the manipulation of receptors and adapters in vaccine therapy.
Keywords: adjuvants – dendritic cells – interferon – microbial pattern molecules – Toll-like receptor
For reprints and all correspondence: Tsukasa Seya, Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638 Japan. Tel: +81-11-706-5073; Fax: +81-11-706-7866; E-mail: seya-tu{at}med.hokudai.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. M. Pletneva, O. Haller, D. D. Porter, G. A. Prince, and J. C. G. Blanco Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats J. Gen. Virol., January 1, 2008; 89(1): 261 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Izadi, A. T. Motameni, T. C. Bates, E. R. Olivera, V. Villar-Suarez, I. Joshi, R. Garg, B. A. Osborne, R. J. Davis, M. Rincon, et al. c-Jun N-Terminal Kinase 1 Is Required for Toll-Like Receptor 1 Gene Expression in Macrophages Infect. Immun., October 1, 2007; 75(10): 5027 - 5034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne The cross-talk between dendritic and regulatory T cells: good or evil? J. Leukoc. Biol., October 1, 2007; 82(4): 781 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Cooper Role of TOLL-like Receptors in Adjuvant-Augmented Immune Therapies by T. Seya. Evid. Based Complement. Altern. Med., March 1, 2006; 3(1): 133 - 137. [Full Text] [PDF]
|
|